Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Sara Tolaney MD, MPH
Sara M. Tolaney MD, MPH Advisory Board
Barbara Burtness MD
Barbara Burtness MD Advisory Board
Jeffrey Kirshner MD, FACP, FASCO
Jeffrey J. Kirshner MD, FACP, FASCO Advisory Board
See All Experts
featured
Published in Oncology

Journal Scan / Research · February 28, 2023

Asciminib vs Bosutinib for Chronic-Phase CML Previously Treated With Two or More Tyrosine Kinase Inhibitors

Leukemia

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Rodrigo Fonseca MD

Leukemia
Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL
Leukemia 2023 Jan 30;[EPub Ahead of Print], A Hochhaus, D Réa, C Boquimpani, Y Minami, JE Cortes, TP Hughes, JF Apperley, E Lomaia, S Voloshin, A Turkina, DW Kim, A Abdo, LM Fogliatto, P le Coutre, K Sasaki, DDH Kim, S Saussele, M Annunziata, N Chaudhri, L Chee, V García-Gutiérrez, S Kapoor, A Allepuz, S Quenet, V Bédoucha, MJ Mauro

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated